Category: Federal Forum Posters
Purpose: According to the Centers for Disease Control and Prevention, excessive alcohol consumption cost the nation $249 billion in 2010. These costs are the result of lost productivity, health care expenses, criminal justice expenses, motor vehicle accidents, and property damage. 77% of these costs were the result of binge drinking (≥ 5 drinks in one occasion for men or ≥ 4 drinks for women). The implementation of a pharmacist-led injectable naltrexone clinic may help decrease these expenses by lowering binge/heavy drinking in the community. A pharmacist-led injectable naltrexone clinic has never been evaluated at an Indian Health Service (IHS) facility.
Methods: An IHS facility has a pharmacist-led injectable naltrexone clinic. Patients must satisfy specific inclusion criteria to be enrolled in the clinic: alcohol use disorder (AUD) based on DSM-5 criteria, 18 years or older, desire to abstain from alcohol, opiate free for 7-10 days in patients with a history of opioid use disorder (OUD), negative urine drug screen (in OUD), negative pregnancy test (in females), and be willing to receive monthly intramuscular injections. Also, patient’s must not be disqualified by the clinic’s exclusion criteria: acute hepatitis, severe hepatic impairment (Child Pugh Class C), creatinine clearance <50 mL/min, unable to tolerate intramuscular injection, current opioid use/dependence, expected to require opioids for pain management, previously documented intolerance/allergy to naltrexone, or conditions that may impair the absorption of the injection. Baseline characteristics will be collected for patients: age, gender, historic alcohol use, past treatments attempted, emergency department (ED) visits/hospital admissions due to alcohol-related reasons in the last 6 months, and enrollment in a treatment program. Primary endpoints collected for enrolled patients will be alcohol use, ED visits, hospital admissions, and treatment adherence. Using descriptive statistics, patients will be compared to themselves (before and after starting treatment) and to patients who have used oral naltrexone.
Results: not applicable
Conclusion: not applicable
Kameron Baker– Pharmacy Resident, Franciscan Health Lafayette, Indianapolis, IN